Today: 20 March 2026
Subscribe
Browse Category

NYSE:DAVA 11 November 2025 - 13 November 2025

Paysafe (PSFE) Tumbles After Q3 2025 Earnings Miss, Guidance Cut and New Endava AI Partnership

Paysafe (PSFE) Tumbles After Q3 2025 Earnings Miss, Guidance Cut and New Endava AI Partnership

Paysafe reported Q3 2025 revenue of $433.8 million, up 2% year-on-year, but its net loss widened to $87.7 million due to an $81 million non-cash tax charge. The company cut its full-year outlook and shares fell as much as 15% before recovering to around $10.16. Paysafe also announced a multi-year AI payments partnership with Endava and expanded its share buyback authorization by $70 million.
13 November 2025
··
Endava (DAVA) Sinks After Q1 FY26 Miss; FY26 Outlook Trimmed as Company Expands TRD U.S.A. Partnership — Nov 11, 2025

Endava (DAVA) Sinks After Q1 FY26 Miss; FY26 Outlook Trimmed as Company Expands TRD U.S.A. Partnership — Nov 11, 2025

Endava reported Q1 FY26 revenue of £178.2M, down 8.6% year-over-year, and cut its full-year outlook, sending shares down over 20% in early trading. IFRS diluted EPS was £(0.15), with adjusted EPS at £0.15, both missing estimates. The company announced a multi-year IT partnership with Toyota Racing Development and a payments deal worth up to $100M.
11 November 2025
··

Stock Market Today

  • Telix Pharmaceuticals Shares Surge 12.9% After TLX101-Px FDA NDA Resubmission and U.S. Manufacturing Expansion
    March 20, 2026, 1:35 PM EDT. Telix Pharmaceuticals (ASX:TLX) jumped 12.9% following its March 2026 resubmission of the New Drug Application (NDA) for TLX101-Px (Pixclara) to the U.S. FDA. The investigational PET imaging agent targets brain cancer diagnosis, specifically glioma, with no current FDA-approved equivalents in the U.S. The resubmission includes new data after a prior Complete Response Letter and benefits from Orphan Drug and Fast Track designations. Concurrently, Telix's U.S. manufacturing build-out, including cyclotron orders for isotope production, aims to scale supply for future launches. While analysts project revenue of A$1.2 billion and earnings of A$111 million by 2029, the company faces risks from heavy R&D and manufacturing investments that may pressure margins if commercialization stalls. Investors are weighing potential near-term catalysts against execution and development uncertainties.
Go toTop